BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15465011)

  • 1. N-Formylated humanin activates both formyl peptide receptor-like 1 and 2.
    Harada M; Habata Y; Hosoya M; Nishi K; Fujii R; Kobayashi M; Hinuma S
    Biochem Biophys Res Commun; 2004 Nov; 324(1):255-61. PubMed ID: 15465011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR.
    Rabiet MJ; Huet E; Boulay F
    Eur J Immunol; 2005 Aug; 35(8):2486-95. PubMed ID: 16025565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formyl peptide receptor like 1 differentially requires mitogen-activated protein kinases for the induction of glial fibrillary acidic protein and interleukin-1alpha in human U87 astrocytoma cells.
    Kam AY; Tse TT; Kwan DH; Wong YH
    Cell Signal; 2007 Oct; 19(10):2106-17. PubMed ID: 17643960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional expression of N-formyl peptide receptors in human bone marrow-derived mesenchymal stem cells.
    Viswanathan A; Painter RG; Lanson NA; Wang G
    Stem Cells; 2007 May; 25(5):1263-9. PubMed ID: 17234990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of Phospholipase D 1 and 2 in the subcellular localization and activity of formyl-peptide-receptors in the human colonic cell line HT29.
    Brandenburg LO; Seyferth S; Wruck CJ; Koch T; Rosenstiel P; Lucius R; Pufe T
    Mol Membr Biol; 2009 Aug; 26(5):371-83. PubMed ID: 19707939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
    Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
    Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
    El Zein N; Badran B; Sariban E
    J Leukoc Biol; 2008 Apr; 83(4):972-81. PubMed ID: 18174366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internalization of PrP106-126 by the formyl-peptide-receptor-like-1 in glial cells.
    Brandenburg LO; Koch T; Sievers J; Lucius R
    J Neurochem; 2007 May; 101(3):718-28. PubMed ID: 17448144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F2L, a peptide derived from heme-binding protein, inhibits formyl peptide receptor-mediated signaling.
    Lee HY; Lee SY; Shin EH; Kim SD; Kim JM; Lee MS; Ryu SH; Bae YS
    Biochem Biophys Res Commun; 2007 Aug; 359(4):985-90. PubMed ID: 17577578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formyl peptide-receptor like-1 requires lipid raft and extracellular signal-regulated protein kinase to activate inhibitor-kappa B kinase in human U87 astrocytoma cells.
    Kam AY; Liu AM; Wong YH
    J Neurochem; 2007 Nov; 103(4):1553-66. PubMed ID: 17727628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FPR2-specific ligand MMK-1 activates the neutrophil NADPH-oxidase, but triggers no unique pathway for opening of plasma membrane calcium channels.
    Karlsson J; Stenfeldt AL; Rabiet MJ; Bylund J; Forsman HF; Dahlgren C
    Cell Calcium; 2009 May; 45(5):431-8. PubMed ID: 19282028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A homolog of formyl peptide receptor-like 1 (FPRL1) inhibitor from Staphylococcus aureus (FPRL1 inhibitory protein) that inhibits FPRL1 and FPR.
    Prat C; Haas PJ; Bestebroer J; de Haas CJ; van Strijp JA; van Kessel KP
    J Immunol; 2009 Nov; 183(10):6569-78. PubMed ID: 19846866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection.
    Hashimoto Y; Suzuki H; Aiso S; Niikura T; Nishimoto I; Matsuoka M
    Life Sci; 2005 Oct; 77(24):3092-104. PubMed ID: 16005025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calpain inhibitors stimulate phagocyte functions via activation of human formyl peptide receptors.
    Fujita H; Kato T; Watanabe N; Takahashi T; Kitagawa S
    Arch Biochem Biophys; 2011 Sep; 513(1):51-60. PubMed ID: 21723247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the ratio between FPR and FPRL1 triggered superoxide production in human neutrophils-a tool in analysing receptor specific events.
    Fu H; Karlsson J; Björkman L; Stenfeldt AL; Karlsson A; Bylund J; Dahlgren C
    J Immunol Methods; 2008 Feb; 331(1-2):50-8. PubMed ID: 18166194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formyl peptide receptor-like 2 is expressed and functional in plasmacytoid dendritic cells, tissue-specific macrophage subpopulations, and eosinophils.
    Devosse T; Guillabert A; D'Haene N; Berton A; De Nadai P; Noel S; Brait M; Franssen JD; Sozzani S; Salmon I; Parmentier M
    J Immunol; 2009 Apr; 182(8):4974-84. PubMed ID: 19342677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel nonpeptide ligand for formyl peptide receptor-like 1.
    Nanamori M; Cheng X; Mei J; Sang H; Xuan Y; Zhou C; Wang MW; Ye RD
    Mol Pharmacol; 2004 Nov; 66(5):1213-22. PubMed ID: 15308762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Trp-Nle-Tyr-Met as a novel agonist for human formyl peptide receptor-like 1.
    Wan HX; Zhou C; Zhang Y; Sun M; Wang X; Yu H; Yang X; Ye RD; Shen JK; Wang MW
    Biochem Pharmacol; 2007 Jul; 74(2):317-26. PubMed ID: 17517377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of human formyl peptide receptors by calpain inhibitors: homology modeling of receptors and ligand docking simulation.
    Fujita H; Kato T; Watanabe N; Takahashi T; Kitagawa S
    Arch Biochem Biophys; 2011 Dec; 516(2):121-7. PubMed ID: 22005393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects.
    Hecht I; Rong J; Sampaio AL; Hermesh C; Rutledge C; Shemesh R; Toporik A; Beiman M; Dassa L; Niv H; Cojocaru G; Zauberman A; Rotman G; Perretti M; Vinten-Johansen J; Cohen Y
    J Pharmacol Exp Ther; 2009 Feb; 328(2):426-34. PubMed ID: 19023040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.